$1.77 Billion is the total value of Bain Capital Life Sciences Investors, LLC's 31 reported holdings in Q1 2021. The portfolio turnover from Q4 2020 to Q1 2021 was 34.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $429,009,000 | -18.8% | 5,831,307 | -19.9% | 24.30% | -26.7% |
| AVIR | ATEA PHARMACEUTICALS, INC. | $346,767,000 | +47.8% | 5,615,659 | 0.0% | 19.64% | +33.4% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS, INC. | $115,121,000 | +2.8% | 3,979,292 | 0.0% | 6.52% | -7.2% | |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $107,105,000 | – | 10,895,773 | +100.0% | 6.07% | – |
| ANNX | ANNEXON INC | $90,247,000 | +11.2% | 3,241,628 | 0.0% | 5.11% | +0.4% | |
| PHVS | New | PHARVARIS N.V. | $88,993,000 | – | 3,180,601 | +100.0% | 5.04% | – |
| DRNA | DICERNA PHARMACEUTICALS INC | $78,762,000 | +16.1% | 3,080,237 | 0.0% | 4.46% | +4.7% | |
| CCCC | C4 THERAPEUTICS, INC. | $60,745,000 | +11.7% | 1,642,209 | 0.0% | 3.44% | +0.7% | |
| MRSN | Buy | MERSANA THERAPEUTICS INC | $59,796,000 | -34.8% | 3,695,667 | +7.3% | 3.39% | -41.2% |
| SLDB | Buy | SOLID BIOSCIENCES INC | $43,852,000 | -18.1% | 7,929,918 | +12.3% | 2.48% | -26.1% |
| SYRS | SYROS PHARMACEUTICALS, INC. | $43,272,000 | -31.1% | 5,785,036 | 0.0% | 2.45% | -37.8% | |
| NRIX | NURIX THERAPEUTICS, INC. | $39,929,000 | -5.4% | 1,284,314 | 0.0% | 2.26% | -14.7% | |
| CNST | CONSTELLATION PHARMACEUTICALS, INC. | $32,746,000 | -18.8% | 1,400,000 | 0.0% | 1.86% | -26.7% | |
| APTX | APTINYX INC | $26,675,000 | -13.3% | 8,891,758 | 0.0% | 1.51% | -21.8% | |
| SVRA | Buy | SAVARA INC | $24,175,000 | +309.9% | 11,622,598 | +126.6% | 1.37% | +270.0% |
| New | MARINUS PHARMACEUTICALS INC | $22,153,000 | – | 1,431,058 | +100.0% | 1.26% | – | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $21,384,000 | +0.6% | 2,700,000 | 0.0% | 1.21% | -9.2% | |
| KYMR | KYMERA THERAPEUTICS INC. | $18,637,000 | -37.3% | 479,605 | 0.0% | 1.06% | -43.4% | |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $18,249,000 | +72.2% | 2,119,540 | +28.6% | 1.03% | +55.5% |
| CRNX | CRINETICS PHARMACEUTICALS INC | $16,371,000 | +8.3% | 1,071,428 | 0.0% | 0.93% | -2.3% | |
| BLUE | New | BLUEBIRD BIO, INC. | $16,226,000 | – | 538,179 | +100.0% | 0.92% | – |
| ARYA | ARYA SCIENCES ACQUISITION CORP III | $13,780,000 | +27.0% | 1,000,000 | 0.0% | 0.78% | +14.7% | |
| RACA | THERAPEUTICS ACQUISITION CORP | $10,510,000 | -24.5% | 1,000,000 | 0.0% | 0.60% | -31.9% | |
| RACB | New | RESEARCH ALLIANCE CORP II | $10,250,000 | – | 1,000,000 | +100.0% | 0.58% | – |
| ARYD | New | ARYA SCIENCES ACQUISITION CORP IVcl a | $7,331,000 | – | 700,000 | +100.0% | 0.42% | – |
| BCTG | BCTG ACQUISITION CORP | $5,560,000 | -2.8% | 500,000 | 0.0% | 0.32% | -12.3% | |
| BLSA | BCLS ACQUISITION CORP | $5,153,000 | -5.1% | 487,500 | 0.0% | 0.29% | -14.4% | |
| OMEG | New | OMEGA ALPHA SPACcl a | $3,960,000 | – | 400,000 | +100.0% | 0.22% | – |
| FLACU | FRAZIER LIFESCIENCES ACQUISITION CORPunit 12/09/2025 | $3,048,000 | -2.1% | 300,000 | 0.0% | 0.17% | -11.7% | |
| JYAC | JIYA ACQUISITION CORP | $2,952,000 | -4.5% | 300,000 | 0.0% | 0.17% | -13.9% | |
| HLXA | HELIX ACQUISITION CORP | $2,550,000 | -10.3% | 250,000 | 0.0% | 0.14% | -19.1% | |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -1,431,058 | -100.0% | -1.10% | – |
| Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -10,895,773 | -100.0% | -3.04% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-05-17
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.